Article
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
The lancet. Gastroenterology & hepatology - 1 Mar 2018
Adams Richard, Brown Ewan, Brown Louise, Butler Rachel, Falk Stephen, Fisher David, Kaplan Richard, Quirke Phil, Richman Susan, Samuel Leslie, Seligmann Jenny, Seymour Matt, Shiu Kai Keen, Wasan Harpreet, Wilson Richard, Maughan Tim
Abstract excerpt
BACKGROUND: A substantial change in trial methodology for solid tumours has taken place, in response to increased understanding of cancer biology. FOCUS4 is a phase 2-3 trial programme testing targeted agents in patients with advanced colorectal cancer in molecularly stratified cohorts. Here, we aimed to test the hypothesis that combined inhibition of EGFR, HER2, and HER3 signalling with the tyrosine kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.